Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBA6 | A0AVT1 | 5/20 | 0.41 |
| ▸ | NAE1 | Q13564 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | GRK5 | P34947 | 1/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.41 |
| ▸ | NEDD8 | Q15843 | 1/20 | 0.41 |
| ▸ | UBA3 | Q8TBC4 | 1/20 | 0.41 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.41 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.39 |
| ▸ | NNMT | P40261 | 6/20 | 0.38 |
| ▸ | TK1 | P04183 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL936138 | 1.00 | UBA6 (0.41) | UBA6NAE1CA2GRK5CSNK1A1 | |
| SCHEMBL18589317 | 1.00 | UBA6 (0.41) | UBA6NAE1CA2GRK5CSNK1A1 | |
| SCHEMBL1795550 | 0.90 | UBA6 (0.40) | UBA6NAE1CA2GRK5CSNK1A1 | |
| SCHEMBL23892218 | 0.88 | PRMT5 (0.47) | UBA6NAE1PRMT5WDR77NNMT | |
| SCHEMBL16943624 | 0.86 | UBA6 (0.41) | UBA6PRMT5WDR77NNMT | |
| SCHEMBL191943 | 0.85 | ADK (0.48) | PRMT5WDR77 | |
| SCHEMBL10186224 | 0.85 | UBA6 (0.42) | UBA6NAE1CA2GRK5CSNK1A1 | |
| SCHEMBL25048671 | 0.85 | UBA6 (0.42) | UBA6NAE1CA2GRK5CSNK1A1 | |
| SCHEMBL19563037 | 0.85 | ADK (0.48) | PRMT5WDR77 | |
| SCHEMBL16769947 | 0.83 | PRMT5 (0.44) | UBA6PRMT5WDR77NNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-11 | — | — | US | disclosed |
| US-20140256668-A9 | SUBSTITUTED PYRROLO]2,3-D]PYRIMIDINES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20130338094-A1 | SUBSTITUTED PYRROLO]2,3-D]PYRIMIDINES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| EP-1848718-B1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARM INC (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20110136834-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136834-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | UBA6 728/4885NAE1 41/4885CA2 3826/4885 |
| US-20140256668-A9 | SUBSTITUTED PYRROLO]2,3-D]PYRIMIDINES | DPYD, CCND3, POLD3 | UBA6 4411/4885NAE1 2945/4885CA2 3232/4885 |
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | UBA6 728/4885NAE1 41/4885CA2 3826/4885 |
| US-20130338094-A1 | SUBSTITUTED PYRROLO]2,3-D]PYRIMIDINES | DPYD, CCND3, POLD3 | UBA6 4411/4885NAE1 2945/4885CA2 3232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.